

HORIZON-J

ANNEX 1

ANNEX 2

ANNEX 3

ANNEX 4

ANNEX 5

ANNEX 6

ANNEX 7

Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

Table 7

Table 8

Call Evaluation Report

U-GH-EDCTP3-2025-01-MALARIA-02-two-stage, HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage, HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage

HORIZON-JU-GH-EDCTP3-2025-01-two-stage

HORIZON-JU-GH-EDCTP3-2025-01-two-stage

9-3-25 17:00 a

Call ranked list(s)

List of below threshold proposals

List of inadmissible proposals

List of ineligible proposals

Evaluation statistics, number of proposals, number of participants and EU requested contribution in evaluated, retained for funding and reserve list proposals

Track list of evaluated proposals

Call specific statistics

Geographic origin and gender of independent experts

Affiliation of independent experts

Gender of coordinators and applicants' person in charge in evaluated and in retained for funding proposals

Applicants' activity type in evaluated and in retained for funding proposals

SME participation in evaluated and in retained for funding proposals

SME coordinators in evaluated and retained for funding proposals

List of participants in evaluated proposals

Country participation and share of requested EU contribution in evaluated and retained for funding proposals

Status	EU Rank	Criteria to determine ranking in case of equal score (only applicable around funding threshold)	Overall score	Overall score, weighted and normalised to 15	Topic	Panel	Step
Main list	1		14,00	14,00	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	1
Main list	2		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	1
Main list	3		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	1
Below available budget	4		12,50	12,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	1
Below available budget	5		12,00	12,00	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	1
Main list	1		15,00	15,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	1
Main list	2		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	1
Main list	3		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	1
Main list	1		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	1
Main list	2		13,00	13,00	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	1
Main list	3		12,50	12,50	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	1
Reserve list	4	Aspects of the call	12,00	12,00	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	1

Reserve list	5		12,00	12,00	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	1
--------------	---	--	-------	-------	--	--	---

ANNEX 1: Call ranked list(s)

Type of Action	Proposal Number	Acronym	Title
HORIZON-JU-RIA	101248917	WANECAM 3	SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS
HORIZON-JU-RIA	101248869	RAMP	Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy
HORIZON-JU-RIA	101248948	CUREMAL	Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins
HORIZON-JU-RIA	101248797	FACT	Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children
HORIZON-JU-RIA	101248967	MIRACLE	Malaria Investigation and Research for Adults, Children, Lactating and Expecting women
HORIZON-JU-RIA	101249063	ACT-CHIK	Accelerating Clinical Trials for CHIKungunya Vaccine in Africa
HORIZON-JU-RIA	101249075	EAVI	EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICA
HORIZON-JU-RIA	101249135	DENSTAR	Dengue Efficacy & Safety Trial in African Region
HORIZON-JU-RIA	101248828	T5-TBVAC	EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS: T5-TBVAC
HORIZON-JU-RIA	101248955	ACTTIVAC	A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa
HORIZON-JU-RIA	101249073	MTBVAC-AVANTE	Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic
HORIZON-JU-RIA	101248871	ADVANCE-TB	Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa

HORIZON-JU-RIA	101248866	SPOTLIGHT	Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites
----------------	-----------	-----------	---

Coordinating organisation	Country coordinator	Duration (months)	Total Cost	Requested EU contribution	Recommended EU Contribution	Cumulative EU Contribution
STICHTING AMSTERDAM UMC	NL	60	27.981.177,50 €	10.296.177,50 €	10.296.177,50 €	10.296.177,50 €
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	FR	60	15.806.856,25 €	10.298.968,75 €	10.298.968,75 €	20.595.146,25 €
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO S.L.	ES	54	22.888.140,75 €	8.417.294,00 €	8.417.294,00 €	29.012.440,25 €
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN	DE	60	10.139.216,25 €	10.139.216,25 €	10.139.216,25 €	39.151.656,50 €
MMV MEDICINES FOR MALARIA VENTURE FOUNDATION	CH	54	35.925.000,00 €	10.300.000,00 €	10.300.000,00 €	49.451.656,50 €
UNIVERSITY OF RWANDA	RW	48	15.299.931,75 €	15.299.931,75 €	15.299.931,75 €	15.299.931,75 €
MEDIZINISCHE UNIVERSITAT INNSBRUCK	AT	60	13.695.935,00 €	13.695.935,00 €	13.695.935,00 €	28.995.866,75 €
SCLAVO VACCINES ASSOCIATION	IT	48	11.091.138,75 €	11.091.138,75 €	11.091.138,75 €	40.087.005,50 €
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF	UK	60	12.687.077,50 €	12.687.077,50 €	12.687.077,50 €	12.687.077,50 €
STICHTING TUBERCULOSIS VACCINE INITIATIVE	NL	48	14.361.817,00 €	11.943.468,75 €	11.943.468,75 €	24.630.546,25 €
BIOFABRI SL	ES	48	75.584.338,75 €	18.223.018,77 €	18.223.018,77 €	42.853.565,02 €
BIONTECH SE	DE	60	39.234.115,25 €	39.234.115,25 €	39.234.115,25 €	82.087.680,27 €

STICHTING TUBERCULOSIS VACCINE INITIATIVE	NL	48	28.266.054,75 €	15.138.800,00 €	15.138.800,00 €	97.226.480,27 €
---	----	----	-----------------	-----------------	-----------------	-----------------

Overall score	Topic	Panel	Type of Action	Proposal number	Acronym
13,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249052	huNEOLEISH
12,50	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248980	TOVax
11,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	101249136	PREVENT
12,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249033	VASA3
11,50	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101249101	AERO-SHIELD
12,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248994	RIVAC
10,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	101249134	TACTIC
9,50	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	101249003	IMPACT
12,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249102	SAVE
9,00	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	101248981	E-STAR
12,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248925	CHIDENVAC
12,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248929	AIDA
11,50	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248979	RepLeisH
11,00	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248806	PROPHVAC-CL

NNEX 2: List(s) of below-threshold proposals

Title	Coordinating organisation	Country coordinator	Duration (months)	Total Cost
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS	ES	60	14.923.995,00 €
The Onchocerciasis Vaccine for Africa	THE UNIVERSITY OF LIVERPOOL	UK	60	14.674.718,00 €
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT	CH	60	10.930.281,25 €
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	UNIVERSITÄTSKLINIKUM HEIDELBERG	DE	60	14.999.760,00 €
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	STICHTING TUBERCULOSIS VACCINE INITIATIVE	NL	60	14.885.037,50 €
Rabies: Innovative Vaccines for Africa Consortium	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	UK	60	15.283.079,50 €
Targeting school-Age Children for malaria Transmission Interruption at Community level	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER	UK	48	14.840.734,50 €
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination	EBERHARD KARLS UNIVERSITÄT TUEBINGEN	DE	60	10.344.571,25 €
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER	UK	60	13.700.392,50 €
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	MEDIZINISCHE UNIVERSITÄT WIEN	AT	60	14.637.956,25 €
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	UK	60	15.753.169,25 €
Advancing Access to Innovations for Dengue Eradication in Africa	INSTITUT PASTEUR	FR	60	15.299.036,25 €
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	INSTITUUT VOOR TROPISCHE GENEESKUNDE	BE	60	15.354.932,75 €
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	EUROPEAN VACCINE INITIATIVE E.V	DE	42	14.110.711,75 €

Requested EU contribution	Justification
14.923.995,00 €	Below Threshold
14.674.718,00 €	Below Threshold
10.930.281,25 €	Below Threshold
14.999.760,00 €	Below Threshold
9.464.128,50 €	Below Threshold
15.283.079,50 €	Below Threshold
6.968.751,55 €	Below Threshold
10.344.571,25 €	Below Threshold
13.590.392,50 €	Below Threshold
9.799.990,49 €	Below Threshold
15.753.169,25 €	Below Threshold
15.299.036,25 €	Below Threshold
15.354.931,50 €	Below Threshold
14.110.711,75 €	Below Threshold

Topic	Panel	Type of Action	Proposal number	Acronym
-------	-------	----------------	-----------------	---------

inadmissible proposals

Title	Duration (months)	Total Cost	Requested EU contribution	Reason(s) for non- admissibility
-------	----------------------	------------	------------------------------	-------------------------------------

Topic	Panel	Type of Action	Proposal number	Acronym
-------	-------	----------------	-----------------	---------

X 4: List of ineligible proposals

Title	Duration (months)	Total Cost	Requested EU contribution
-------	----------------------	------------	---------------------------

Reason(s) for ineligibility

ANNEX 5: Evaluation statistics, number of proposals, number of participant

Topic	Panel	Type of Action	Number of proposals evaluated	Number of proposals retained for funding	Success Rate	Number of proposals in reserve list
HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	9	3	33,33 %	0
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	12	3	25,00 %	0
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	6	3	50,00 %	2
TOTAL			27	9	33,33 %	2

its and EU requested contribution in evaluated, retained for funding and reserve list proposals

Number of participants in evaluated proposals	Number of participants in retained for funding proposals	Success Rate	Number of participants in proposals in reserve list	Requested EU contribution in evaluated proposals	Requested EU contribution in retained for funding proposals	Recommended EU contribution in retained for funding proposals	Success Rate	Requested EU contribution in proposals in reserve list
95	38	40,00 %	0	87.495.251,04 €	29.012.440,25 €	29.012.440,25 €	33,16 %	0,00 €
105	26	24,76 %	0	174.076.799,25 €	40.087.005,50 €	40.087.005,50 €	23,03 %	0,00 €
47	24	51,06 %	17	106.690.608,77 €	42.853.565,02 €	42.853.565,02 €	40,17 %	54.372.915,25 €
247	88	35,63 %	17	368.262.659,06 €	111.953.010,77 €	111.953.010,77 €	30,40 %	54.372.915,25 €

**Recommended EU
contribution in
proposals in
reserve list**

54.372.915,25 €

54.372.915,25 €

Topic	Panel	Type of Action	Proposal number	Acronym
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249063	ACT-CHIK
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248955	ACTTIVAC
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248871	ADVANCE-TB
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101249101	AERO-SHIELD
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248929	AIDA
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248925	CHIDENVAC
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101248948	CUREMAL
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249135	DENSTAR
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101248981	E-STAR
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249075	EAVI
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101248797	FACT
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101249003	IMPACT
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101248967	MIRACLE
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101249073	MTBVAC-AVANTE
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101249136	PREVENT
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248806	PROPHVAC-CL
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101248869	RAMP
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248994	RIVAC
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248979	RepLeisH
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249102	SAVE
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248828	T5-TBVAC
HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAI ARIA-02-two-stage	HORIZON-JU-RIA	101249134	TACTIC
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101248980	TOVax
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249033	VASA3

HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-RIA	101248917	WANECAM 3
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-RIA	101249052	huNEOLEISH

ANNEX 6: Track list of evaluated proposals

Title	Duration (months)	Coordinating organisation	Country coordinator	Number of participants	Total eligible costs
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	48	UNIVERSITY OF RWANDA	RW	8	15.299.931,75 €
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GI A-SF Tuberculosis Vaccine for Further Clinical	48	STICHTING TUBERCULOSIS	NL	7	14.361.817,00 €
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	60	BIONTECH SE	DE	11	39.234.115,25 €
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center randomized double-blind placebo-controlled phase	60	STICHTING TUBERCULOSIS	NL	6	14.885.037,50 €
Advancing Access to Innovations for Dengue Eradication in Africa	60	INSTITUT PASTEUR	FR	8	15.299.036,25 €
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative	60	THE CHANCELLOR	UK	6	15.753.169,25 €
Innovative Transformative CURE for Malaria: Rapid-Action Combinations to Replace Artemisinins	54	GLAXOSMITHKLINE INVESTIGACION	ES	10	22.888.140,75 €
Dengue Efficacy & Safety Trial in African Region	48	SCLAVO VACCINES	IT	10	11.091.138,75 €
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	60	MEDIZINISCHE UNIVERSITÄT	AT	16	14.637.956,25 €
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-	60	MEDIZINISCHE UNIVERSITÄT	AT	8	13.695.935,00 €
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections	60	BERNHARD-NOCHT-INSTITUT	DE	10	10.139.216,25 €
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination	60	EBERHARD KARLS	DE	8	10.344.571,25 €
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	54	MMV MEDICINES FOR MALARIA	CH	11	35.925.000,00 €
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	48	BIOFABRI SL	ES	13	75.584.338,75 €
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	60	SCHWEIZERISCHES TROPEN UND	CH	6	10.930.281,25 €
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	42	EUROPEAN VACCINE	DE	7	14.110.711,75 €
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	60	INSTITUT NATIONAL DE LA	FR	17	15.806.856,25 €
Rabies: Innovative Vaccines for Africa Consortium	60	THE CHANCELLOR	UK	7	15.283.079,50 €
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	60	INSTITUUT VOOR TROPISCHE	BE	10	15.354.932,75 €
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	60	LONDON SCHOOL OF HYGIENE AND	UK	6	13.700.392,50 €
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAE10b Including in younger and older age groups in high burden Trial	48	STICHTING TUBERCULOSIS	NL	6	28.266.054,75 €
EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS:	60	THE CHANCELLOR	UK	4	12.687.077,50 €
Targeting school-Age Children for malaria Transmission Interruption at Community level	48	LONDON SCHOOL OF HYGIENE AND	UK	6	14.840.734,50 €
The Onchocerciasis Vaccine for Africa	60	THE UNIVERSITY OF LIVERPOOL	UK	13	14.674.718,00 €
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of	60	UNIVERSITÄT SKLI NIKLIM	DE	9	14.999.760,00 €

SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	60	STICHTING AMSTERDAM	NL	11	27.981.177,50 €
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	60	AGENCIA ESTATAL	ES	13	14.923.995,00 €

Requested EU contribution	Recommended EU contribution	Final Score	Panel Rank	EU Rank	Status
15.299.931,75 €	15.299.931,75 €	15,00	1	1	Main list
11.943.468,75 €	11.943.468,75 €	13,00	2	2	Main list
39.234.115,25 €	39.234.115,25 €	12,00	4	4	Reserve list
9.464.128,50 €		11,50	6	6	Below Threshold
15.299.036,25 €		12,00	10	10	Below Threshold
15.753.169,25 €		12,00	9	9	Below Threshold
8.417.294,00 €	8.417.294,00 €	13,50	3	3	Main list
11.091.138,75 €	11.091.138,75 €	14,50	3	3	Main list
9.799.990,49 €		9,00	9	9	Below Threshold
13.695.935,00 €	13.695.935,00 €	14,50	2	2	Main list
10.139.216,25 €		12,50	4	4	Below available budget
10.344.571,25 €		9,50	8	8	Below Threshold
10.300.000,00 €		12,00	5	5	Below available budget
18.223.018,77 €	18.223.018,77 €	12,50	3	3	Main list
10.930.281,25 €		11,50	6	6	Below Threshold
14.110.711,75 €		11,00	12	12	Below Threshold
10.298.968,75 €	10.298.968,75 €	13,50	2	2	Main list
15.283.079,50 €		12,00	7	7	Below Threshold
15.354.931,50 €		11,50	11	11	Below Threshold
13.590.392,50 €		12,00	8	8	Below Threshold
15.138.800,00 €	15.138.800,00 €	12,00	5	5	Reserve list
12.687.077,50 €	12.687.077,50 €	13,50	1	1	Main list
6.968.751,55 €		10,50	7	7	Below Threshold
14.674.718,00 €		12,50	5	5	Below Threshold
14.999.760,00 €		12,00	6	6	Below Threshold

10.296.177,50 €	10.296.177,50 €	14,00	1	1	Main list
14.923.995,00 €		13,00	4	4	Below Threshold

ANNEX 7 Table 1: Geographic origin and gender of independent experts

Country group	Country	Number of female experts	%	Number of male experts	%	Total
Associated Countries	Norway	0	0,00 %	1	100,00 %	1
Associated Countries	United Kingdom	0	0,00 %	1	100,00 %	1
Associated Countries		0	0,00 %	2	100,00 %	2
EU Member States	Belgium	0	0,00 %	2	100,00 %	2
EU Member States	Denmark	1	100,00 %	0	0,00 %	1
EU Member States	Finland	1	100,00 %	0	0,00 %	1
EU Member States	France	1	50,00 %	1	50,00 %	2
EU Member States	Greece	1	100,00 %	0	0,00 %	1
EU Member States	Ireland	1	100,00 %	0	0,00 %	1
EU Member States	Italy	0	0,00 %	2	100,00 %	2
EU Member States	Portugal	1	100,00 %	0	0,00 %	1
EU Member States	Spain	1	50,00 %	1	50,00 %	2
EU Member States		7	53,85 %	6	46,15 %	13
Third countries	Benin	0	0,00 %	1	100,00 %	1
Third countries	Burundi	0	0,00 %	0	0,00 %	2
Third countries	Cameroon	0	0,00 %	0	0,00 %	1
Third countries	Congo (Democratic Republic of)	0	0,00 %	1	100,00 %	1

Third countries	Eswatini	0	0,00 %	1	100,00 %	1
Third countries	Ethiopia	0	0,00 %	1	100,00 %	1
Third countries	India	0	0,00 %	1	100,00 %	1
Third countries	Kenya	0	0,00 %	1	100,00 %	1
Third countries	Malawi	0	0,00 %	1	100,00 %	1
Third countries	Nigeria	2	40,00 %	3	60,00 %	5
Third countries	Philippines	1	100,00 %	0	0,00 %	1
Third countries	South Africa	0	0,00 %	1	50,00 %	2
Third countries	Tanzania (United Republic of)	0	0,00 %	1	100,00 %	1
Third countries	United States	0	0,00 %	0	0,00 %	1
Third countries	Uruguay	1	100,00 %	0	0,00 %	1
Third countries	Zambia	0	0,00 %	0	0,00 %	1
Third countries	Zimbabwe	0	0,00 %	1	100,00 %	1
Third countries		4	17,39 %	13	56,52 %	23
GRAND TOTAL		11	28,95 %	21	55,26 %	38

ANNEX 7 Table 2: Affiliation of independent experts

Country group	Organisation Country	Number of experts from Higher education	%	Number of experts from Research organisations	%	Number of experts from Non-research public bodies	%
		2	15,38 %	1	7,69 %	2	15,38 %
		2	15,38 %	1	7,69 %	2	15,38 %
Third countries	CA	0	0,00 %	0	0,00 %	0	0,00 %
Third countries	CH	0	0,00 %	1	50,00 %	0	0,00 %
Third countries	GA	0	0,00 %	1	100,00 %	0	0,00 %
Third countries	KE	0	0,00 %	0	0,00 %	0	0,00 %
Third countries	MW	0	0,00 %	1	100,00 %	0	0,00 %
Third countries	NG	1	33,33 %	1	33,33 %	1	33,33 %
Third countries	US	0	0,00 %	0	0,00 %	1	100,00 %
Third countries	ZA	0	0,00 %	1	100,00 %	0	0,00 %
Third countries		1	9,09 %	5	45,45 %	2	18,18 %
EU Member States	DE	1	50,00 %	0	0,00 %	0	0,00 %
EU Member States	DK	1	100,00 %	0	0,00 %	0	0,00 %
EU Member States	ES	0	0,00 %	1	50,00 %	0	0,00 %
EU Member States	FI	0	0,00 %	0	0,00 %	1	100,00 %
EU Member States	IE	2	100,00 %	0	0,00 %	0	0,00 %
EU Member States	IT	1	50,00 %	0	0,00 %	0	0,00 %

EU Member States	LU	0	0,00 %	1	100,00 %	0	0,00 %
EU Member States		5	45,45 %	2	18,18 %	1	9,09 %
Associated Countries	NO	1	50,00 %	1	50,00 %	0	0,00 %
Associated Countries	UK	1	100,00 %	0	0,00 %	0	0,00 %
Associated Countries		2	66,67 %	1	33,33 %	0	0,00 %
GRAND TOTAL		10	26,32 %	9	23,68 %	5	13,16 %

Number of experts from Non-research private bodies	%	Number of experts from Other type of organisation	%	Total
0	0,00 %	5	38,46 %	13
0	0,00 %	5	38,46 %	13
0	0,00 %	1	100,00 %	1
0	0,00 %	1	50,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	3
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	2	18,18 %	11
1	50,00 %	0	0,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	1	50,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	2
0	0,00 %	1	50,00 %	2

0	0,00 %	0	0,00 %	1
1	9,09 %	2	18,18 %	11
0	0,00 %	0	0,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	3
1	2,63 %	9	23,68 %	38

**ANNEX 7 Table 3: Gender of coordinators and applicants' person in charge in evaluated and in the retained for funding p
only for MSCA-IE)**

	Number of coordinators in evaluated proposals	Number of coordinators in retained proposals	Success rate	Number of participants in evaluated proposals	Number of participants in retained proposals	Success rate
Female	12	5	41,67 %	92	39	42,39 %
Male	15	4	26,67 %	140	44	31,43 %
TOTAL	27	9	33,33 %	232	83	35,78 %

roposals (including gender or researchers

Topic	Panel	Type of Action	Number of participants from Higher or secondary education in evaluated proposals	% (out of total participants)	Number of participants from Higher or secondary education in retained for funding proposals	% (out of total participants in retained proposals)
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	Research and Innovation Actions	9	9,78 %	5	20,00 %
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	Research and Innovation Actions	46	50,00 %	7	28,00 %
HORIZON-JU-GH-EDCTP3-2025-01-MAL ARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MAL ARIA-02-two-stage	Research and Innovation Actions	37	40,22 %	13	52,00 %
TOTAL			92	100,00 %	25	100,00 %

ANNEX 7 Table 4: Applicants' activity type in evaluated and in retained for funding proposals

Success rate	Number of participants from Research organisations in evaluated proposals	% (out of total participants)	Number of participants from Research organisations in retained for funding proposals	% (out of total participants in retained proposals)	Success rate	Number of participants from Private for profit organisations (excl. education) in evaluated proposals	% (out of total participants)	Number of participants from Private for profit organisations (excl. education) in retained for funding proposals	% (out of total participants in retained proposals)	Success rate
55,56 %	24	25,81 %	10	25,00 %	41,67 %	5	20,00 %	3	33,33 %	60,00 %
15,22 %	35	37,63 %	13	32,50 %	37,14 %	11	44,00 %	3	33,33 %	27,27 %
35,14 %	34	36,56 %	17	42,50 %	50,00 %	9	36,00 %	3	33,33 %	33,33 %
27,17 %	93	100,00 %	40	100,00 %	43,01 %	25	100,00 %	9	100,00 %	36,00 %

Number of participants from Public body (excl. research and education) in evaluated proposals	% (out of total participants)	Number of participants from Public body (excl. research and education) in retained for funding proposals	% (out of total participants in retained proposals)	Success rate	Number of participants from Other type of organisation in evaluated proposals	% (out of total participants)	Number of participants from Other type of organisation in retained for funding proposals	% (out of total participants in retained proposals)	Success rate
0	0,00 %	0	0,00 %	0,00 %	9	36,00 %	6	60,00 %	66,67 %
4	33,33 %	2	50,00 %	50,00 %	9	36,00 %	1	10,00 %	11,11 %
8	66,67 %	2	50,00 %	25,00 %	7	28,00 %	3	30,00 %	42,86 %
12	100,00 %	4	100,00 %	33,33 %	25	100,00 %	10	100,00 %	40,00 %

Total number of participants in evaluated proposals	Total number of participants in retained for funding proposals	Success rate
47	24	51,06 %
105	26	24,76 %
95	38	40,00 %
247	88	35,63 %

ANNEX 7 Table 5: SME pa

Topic	Panel	Type of Action	Total number of participants in evaluated proposals	Total requested EU contribution of evaluated proposals	Number of SMEs in evaluated proposals	% (of SMEs in evaluated proposals)
HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage	Research and Innovation Actions	95	87.495.251,04 €	2	2,11 %
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	Research and Innovation Actions	105	174.076.799,25 €	4	3,81 %
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	Research and Innovation Actions	47	106.690.608,77 €	3	6,38 %
TOTAL			247	368.262.659,06 €	9	3,64 %

Participation in evaluated and in retained for funding proposals

Total requested EU contribution of SMEs in evaluated proposals	% (share of SMEs requested EU contribution in evaluated proposals)	Total number of participants in retained for funding proposals	Total requested EU contribution of retained for funding proposals	Number of SMEs in retained for funding proposals	% (of SMEs in retained for funding proposals)	Total requested EU contribution of SMEs in retained for funding proposals	% (share of SMEs requested EU contribution in retained for funding proposals)	Success rate of total participants	Success rate of Requested EU contribution
1.022.312,50 €	1,17 %	38	29.012.440,25 €	0	0,00 %			40,00 %	100,00 %
6.646.297,50 €	3,82 %	26	40.087.005,50 €	1	3,85 %	401.878,75 €	1,00 %	24,76 %	100,00 %
25.498.413,25 €	23,90 %	24	42.853.565,02 €	1	4,17 %	3.199.427,00 €	7,47 %	51,06 %	100,00 %
33.167.023,25 €	9,01 %	88	111.953.010,77 €	2	2,27 %	3.601.305,75 €	3,22 %	35,63 %	100,00 %

Success rate of SMEs participants	%
0,00 %	
0,00 %	
33,33 %	
22,22 %	

ANNEX 7 Table 6: SME coordinators in evaluated and retained for funding propos

Topic	Panel	Type of Action	Total coordinators in evaluated proposals	Total SME coordinators in evaluated proposals	% SME coordinators in evaluated proposals	Total coordinators in retained for funding proposals
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	Research and Innovation Actions	6	1	16,67 %	3
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage	Research and Innovation Actions	12	0	0,00 %	3
HORIZON-JU-GH-EDCTP3-2025-01-MAL ARIA-02-two-	HORIZON-JU-GH-EDCTP3-2025-01-MAL ARIA-02-two-stage	Research and Innovation Actions	9	0	0,00 %	3
TOTAL			27	1	3,70 %	9

als

Total SME coordinators in retained for funding proposals	% SME coordinators in retained for funding proposals	Success rate coordinators	Success rate SME coordinators
0	0,00 %	50,00 %	0,00 %
0	0,00 %	25,00 %	0,00 %
0	0,00 %	33,33 %	0,00 %
0	0,00 %	33,33 %	0,00 %

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248866	SPOTLIGHT
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248828	T5-TBVAC
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248828	T5-TBVAC
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248828	T5-TBVAC
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage	HORIZON-JU-RIA	101248828	T5-TBVAC

ANNEX 7 Table 7: List of participants in evaluated proposals

Title	Status	Participant role	Country	Business name	Legal name
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Coordinator	ES	GSK	GLAXOSMITHKLINE INVESTIGACIONES
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	ES	ISGLOBAL	FUNDACION PRIVADA INSTITUTO DE
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	CH	MMV	MMV MEDICINES FOR MALARIA
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	DE	UT	EBERHARD KARLS UNIVERSITAET
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	GA	CERMEL	Centre de Recherches Medicales de
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	UG	IDRC	INFECTIOUS DISEASES RESEARCH
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	MZ	CISM (FM)	FUNDACAO MANHICA
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	UK	WSI (GRL)	GENOME RESEARCH LIMITED LTD
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins	Main list	Participant	ZA	CERI (SU UNIVERSITY OF	STELLENBOSCH UNIVERSITY
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Coordinator	AT	MUW	MEDIZINISCHE UNIVERSITAET WIEN
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	UG	MCRI	Mbale Clinical Research Institute
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	UK	UOXF	THE CHANCELLOR, MASTERS AND
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GH	KNUST	KWAME NKRUMAH UNIVERSITY OF
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	ET	HU	HAWASSA UNIVERSITY
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	MW	KUHeS	KAMUZU UNIVERSITY OF HEALTH
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GM	MRCG	Medical Research Council Unit The

ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GW	INASA	INSTITUTO NACIONAL DE SAUDE
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	BF	CRUN	Clinical Research Unit of Nanoro
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GA	CERMEL	Centre de Recherches Medicales de
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	DE	LINQ MANAGEMENT T GMBH	LINQ MANAGEMENT GMBH
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	UG	MoHU	MINISTRY OF HEALTH
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GM	MoHSWG	Ministry of Health and Social Welfare
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	ET	MoHE	MINISTRY OF HEALTH
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GW	MSPGB	MINISTERIO DA SAUDE PUBLICA
ENHANCED SURVEILLANCE AND TREATMENT ADAPTATION FOR ARTEMISININ RESISTANCE IN AFRICA	Below Threshold	Participant	GH	NMEPG	National Malaria Elimination Programme
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Coordinator	DE	BNITM	BERNHARD-NOCHT-INSTITUT FUER
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	GA	CERMEL	Centre de Recherches Medicales de
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	DE	UT	EBERHARD KARLS UNIVERSITAET
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	CG	FCRM	FONDATION CONGOLAISE POUR LA
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	GH	KNUST	KWAME NKUMAH UNIVERSITY OF
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	DE	UHAM	UNIVERSITY OF HAMBURG
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	AT	MUW	MEDIZINISCHE UNIVERSITAET WIEN
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	ET	AAU	ADDIS ABABA UNIVERSITY
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant	DE	EURICE	EURICE EUROPEAN RESEARCH
Antibiotic-based combination therapy fosmidomycin-artesunate-clindamycin for the concurrent treatment of severe malaria and bacterial blood stream infections in African children	Below available budget	Participant - AP	DE	DMG Deutsche Malaria GmbH	DMG Deutsche Malaria GmbH
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Coordinator	DE	UT	EBERHARD KARLS UNIVERSITAET

IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	TZ	MUHAS	MUHIMBILI UNIVERSITY OF HEALTH AND
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	UG	IDRC	INFECTIOUS DISEASES RESEARCH
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	BI	INSP	INSTITUT NATIONAL DE SANTE
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	UK	IC	IMPERIAL COLLEGE OF SCIENCE
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	FR	UNISTRA	UNIVERSITE DE STRASBOURG
IMPact of Multiple First-Line Therapy alone or in combination With Primaquine on containing resistance to Artemisinin-Based Combination therapy (ACT) In East Africa	Below Threshold	Participant	SE	UU	UPPSALA UNIVERSITET
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Coordinator	CH	MMV	MMV MEDICINES FOR MALARIA
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	CH	NOVARTIS	NOVARTIS PHARMA AG
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	UK	LIVERPOOL SCHOOL OF TROPICAL	LIVERPOOL SCHOOL OF TROPICAL
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant - AF	KE	LIVERPOOL SCHOOL OF TROPICAL	LIVERPOOL SCHOOL OF TROPICAL
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	UG	IDRC	INFECTIOUS DISEASES RESEARCH
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	BF	CENTRE NATIONAL DE RECHERCHE	CENTRE NATIONAL DE RECHERCHE
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	CD	UNIKIN	UNIVERSITE DE KINSHASA
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	BF	INSTITUT NATIONAL DE SANTE	INSTITUT NATIONAL DE SANTE
Malaria Investigation and Research for Adults, Children, Lactating and Expecting women	Below available budget	Participant	CI	MSHPCMU	MINISTERE DE LA SANTE DE L'HYGIENE
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Coordinator	CH	Swiss TPH	SCHWEIZERISC HES TROPEN UND PUBLIC
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Participant	GH	UNIVERSITY OF HEALTH AND ALLIED	UNIVERSITY OF HEALTH AND ALLIED

PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Participant	TZ	IHI	THE REGISTERED TRUSTEES OF
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Participant	ES	ISGLOBAL	FUNDACION PRIVADA INSTITUTO DE
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Participant	CD	Ecole de Santé Publique de Kinshasa	Ecole de Santé Publique de Kinshasa
PREVENTION AND REDUCTION OF MALARIA THROUGH VACCINATION AND CHEMOTHERAPY	Below Threshold	Participant	MZ	FM	FUNDACAO MANHICA
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Coordinator	FR	INSERM	INSTITUT NATIONAL DE LA SANTE ET
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant - AF	FR	UPCité	UNIVERSITE PARIS CITE
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant - AF	FR	USPN	UNIVERSITE PARIS 13
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	GH	KCCR/KNUST	KWAME NKRUMAH UNIVERSITY OF
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant - AF	ML	PDNA	Pathogens genomic Diversity Network
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	FR	EPICENTRE	EPICENTRE
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	EG	PHARCO	Pharco Pharmaceuticals
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	FR	IRBA	Institut de Recherche Biomédicale des
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	DE	UT	EBERHARD KARLS UNIVERSITAET
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	DE	UKHD	UNIVERSITÄTS KLINIKUM HEIDELBERG
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	FR	IRD	INSTITUT DE RECHERCHE POUR LE
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant - AF	FR	CNRS	CENTRE NATIONAL DE LA RECHERCHE
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	GA	CERMEL	Centre de Recherches Médicales de
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	UG	Epicentre Mbarara Research	Epicentre Mbarara Research Centre
Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	ML	National Malaria Control Program	National Malaria Control Program (NMCP)

Ravidasvir to combat the emergence and spread of artemisinin resistance in Africa: a phase 2 and 3 clinical trial to assess its efficacy	Main list	Participant	GH	GHANA HEALTH SERVICE	GHANA HEALTH SERVICE
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Coordinator	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Participant	UK	LIVERPOOL SCHOOL OF TROPICAL MEDICINE	LIVERPOOL SCHOOL OF TROPICAL MEDICINE
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Participant	BF	GRAS	GROUPE DE RECHERCHE ACTION EN SANTE
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Participant	UG	IDRC	INFECTIONIOUS DISEASES RESEARCH CENTRE
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Participant	NL	RADBOUDUM C	STICHTING RADBOUD UNIVERSITEIT
Targeting school-Age Children for malaria Transmission Interruption at Community level	Below Threshold	Participant - AP	US	LOS ANGELES UCLA SANTA MONICA	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Coordinator	NL	STICHTING AMSTERDAM UMC	STICHTING AMSTERDAM UMC
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES SCIENCES
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	CH	NOVARTIS	NOVARTIS PHARMA AG
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	CH	MMV	MMV MEDICINES FOR MALARIA
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	ET	AAU	ADDIS ABABA UNIVERSITY
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	GA	CERMEL	Centre de Recherches Medicales de l'Etat
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	BF	Groupe de Recherche Action en Sante	Groupe de Recherche Action en Sante
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	KE	HEALTH RESEARCH OPERATIONS	HEALTH RESEARCH OPERATIONS
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	UG	MAKERERE	MAKERERE UNIVERSITY
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
SINGLE DOSE CURE OF FALCIPARUM MALARIA USING NEXT GENERATION COMBINATIONS	Main list	Participant	DE	UT	EBERHARD KARLS UNIVERSITAET
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Coordinator	RW	UNIVERSITY OF RWANDA	UNIVERSITY OF RWANDA
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	FR	IP	INSTITUT PASTEUR

Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	SN	INSTITUT PASTEUR DE DAKAR	INSTITUT PASTEUR DE DAKAR
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	BR	FIOCRUZ	FUNDACAO OSWALDO CRUZ
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	NG	IRRUA SPECIALIST TEACHING	IRRUA SPECIALIST TEACHING
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	NG	Federal Teaching Hospital	Alex Ekwueme Federal University
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
Accelerating Clinical Trials for CHIKungunya Vaccine in Africa	Main list	Participant	KR	IVI	INTERNATIONAL VACCINE INSTITUTE
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Coordinator	FR	IP Paris	INSTITUT PASTEUR
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	SN	IP Dakar	INSTITUT PASTEUR DE DAKAR
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	RW	Akagera Medicines, Africa	Akagera Medicines Africa
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	DE	UHEI	RUPRECHT-KARLS-UNIVERSITAET
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	BE	UANTWERPEN	UNIVERSITEIT ANTWERPEN
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	UK	MRC Gambia	LONDON SCHOOL OF HYGIENE AND
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	FR	Pasteur Network	PASTEUR NETWORK
Advancing Access to Innovations for Dengue Eradication in Africa	Below Threshold	Participant	FR	V4C	V4C
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Coordinator	UK	UOXF	THE CHANCELLOR, MASTERS AND
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Participant	IT	R-EVOWW	R-EVOLUTION WORLDWIDE SRL IMPRESA
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Participant	BF	CENTRE NATIONAL DE RECHERCHE	CENTRE NATIONAL DE RECHERCHE
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES
Advancing mRNA-Based Chikungunya and Dengue Vaccines for Sub-Saharan Africa: A Multi Arm Clinical and Capacity-Building Initiative.	Below Threshold	Participant	KE	HEALTH RESEARCH OPERATIONS	HEALTH RESEARCH OPERATIONS

Dengue Efficacy & Safety Trial in African Region	Main list	Coordinator	IT	SVA	SCLAVO VACCINES ASSOCIATION
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	IN	Panacea Biotech	Panacea Biotec Limited
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	US	JOHNS HOPKINS UNIVERSITY	JOHNS HOPKINS UNIVERSITY
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	US	NATIONAL INSTITUTE OF ALLERGY	NATIONAL INSTITUTE OF ALLERGY AND
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	GA	CERMEL	Centre de Recherches Medicales de
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	MZ	INS	Instituto Nacional de Saúde
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	GH	KNUST	KWAME NKRUMAH UNIVERSITY OF
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	DE	UKHD	UNIVERSITÄTS KLINIKUM HEIDELBERG
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	KR	IVI	INTERNATIONA L VACCINE INSTITUTE
Dengue Efficacy & Safety Trial in African Region	Main list	Participant	CD	INRB	INSTITUT NATIONAL DE RECHERCHE
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Coordinator	AT	MUI	MEDIZINISCHE UNIVERSITÄT INNSBRUCK
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	AT	VLA	VALNEVA AUSTRIA GMBH
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	CH	EPFL	ECOLE POLYTECHNIQ UE FEDERALE
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	ES	ISCIH	INSTITUTO DE SALUD CARLOS III
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	SE	KI	KAROLINSKA INSTITUTET
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB- SAHARAN AFRICA	Main list	Participant	FR	Pikado Writing	Pikado Writing
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Coordinator	DE	EUROPEAN VACCINE INITIATIVE G.V.	EUROPEAN VACCINE INITIATIVE G.V.
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	GH	UNIVERSITY OF GHANA	UNIVERSITY OF GHANA

Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	UK	AAHI	Access to Advanced Health (UK) LTD
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	ES	Instituto de Salud Carlos III ISCIII	INSTITUTO DE SALUD CARLOS III
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	ET	ARMAUER HANSEN RESEARCH	ARMAUER HANSEN RESEARCH
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	ZA	Afrigen Biologics Pty Ltd	Afrigen Biologics Pty Ltd
Advancing the clinical evaluation of a prophylactic vaccine for cutaneous leishmaniasis in sub-Saharan Africa	Below Threshold	Participant	ZA	Bioinformatico (Pty) LTD	Bioinformatico
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Coordinator	UK	UOXF	THE CHANCELLOR, MASTERS AND
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	ZA	Afrigen Biologics Pty Ltd	Afrigen Biologics Pty Ltd
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	BF	CNRST/IRSS-DRCO/Clinical Research Unit	Clinical Research Unit of Nanoro
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	BE	QUANTOOM BIOSCIENCES	QUANTOOM BIOSCIENCES
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	BE	ITM	INSTITUUT VOOR TROPISCHE
Rabies: Innovative Vaccines for Africa Consortium	Below Threshold	Participant	BE	ULB	UNIVERSITE LIBRE DE BRUXELLES
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Coordinator	BE	ITM	INSTITUUT VOOR TROPISCHE
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	UK	KEELE UNIVERSITY	UNIVERSITY OF KEELE ROYAL CHARTER
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	UK	UNIVERSITY OF YORK	UNIVERSITY OF YORK
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	ET	GONDAR UNIVERSITY UOC	UNIVERSITY OF GONDAR
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	ET	ARMAUER HANSEN RESEARCH	ARMAUER HANSEN RESEARCH
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	UK	UNIVERSITY OF WARWICK	UNIVERSITY OF WARWICK
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	ET	Mekelle university	MEKELLE UNIVERSITY
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	UK	UHULL	UNIVERSITY OF HULL

Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant - AP	US	HDT Bio Corp	HDT Bio Corp.
Development of a replicon RNA vaccine to prevent cutaneous leishmaniasis	Below Threshold	Participant	ET	AMU	ARBAMINCH UNIVERSITY*AMU
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Coordinator	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Participant	AT	MEDIZINISCHE E UNIVERSITÄT	MEDIZINISCHE UNIVERSITÄT WIEN
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Participant	GM	Medical Research Council Unit	Medical Research Council Unit The
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Participant	US	UNC	THE UNIVERSITY OF NORTH
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Participant	US	Vaxcyte Inc	Vaxcyte Inc
Accelerating the development of a vaccine for sustainable trachoma elimination: A Sustainable Approach to Vaccine-based Elimination of Trachoma (SAVE)	Below Threshold	Participant	TZ	KILIMANJARO CHRISTIAN MEDICAL	THE GOOD SAMARITAN FOUNDATION
The Onchocerciasis Vaccine for Africa	Below Threshold	Coordinator	UK	THE UNIVERSITY OF	THE UNIVERSITY OF LIVERPOOL
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	DE	EURICE EUROPEAN RESEARCH	EURICE EUROPEAN RESEARCH
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	MW	KAMUZU UNIVERSITY OF HEALTH	KAMUZU UNIVERSITY OF HEALTH
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	CM	UB	UNIVERSITY OF BUEA
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	DE	UKB	UNIVERSITÄT KLINIKUM BONN
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	UK	UNIVERSITY OF GLASGOW	UNIVERSITY OF GLASGOW
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	UK	IMPERIAL COLLEGE OF SCIENCE	IMPERIAL COLLEGE OF SCIENCE
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	CZ	CU	UNIVERZITA KARLOVA
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	IE	SIGHTSAVER S IRELAND	SIGHTSAVERS IRELAND
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant	ZA	Afrigen Biologics Pty Ltd	Afrigen Biologics Pty Ltd
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant - AP	MW	MMOH	Malawi Ministry of Health
The Onchocerciasis Vaccine for Africa	Below Threshold	Participant - AP	US	New York Blood Center, Inc	New York Blood Center, Inc.

The Onchocerciasis Vaccine for Africa	Below Threshold	Participant - AP	US	UCI	THE REGENTS OF THE UNIVERSITY OF
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Coordinator	DE	UKHD	UNIVERSITÄTS KLINIKUM HEIDELBERG
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	MZ	INS	Instituto Nacional de Saúde
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	CD	INRB	INSTITUT NATIONAL DE RECHERCHE
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	MG	UNIVERSITY OF ANTANANARIV	UNIVERSITY OF ANTANANARIV
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	GH	KNUST	KWAME NKRUMAH UNIVERSITY OF
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	SE	KI	KAROLINSKA INSTITUTET
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	UK	THE CHANCELLOR MASTERS	THE CHANCELLOR MASTERS AND
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	US	TEXAS TECH UNIVERSITY SYSTEM	TEXAS TECH UNIVERSITY SYSTEM
Vaccine Against Schistosomiasis for Africa – A multi-center Phase 3 clinical study of the SchistoShield® anti-schistosomiasis vaccine in endemic areas of sub-Saharan Africa	Below Threshold	Participant	KR	IVI	INTERNATIONA L VACCINE INSTITUTE
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Coordinator	ES	CSIC	AGENCIA ESTATAL CONSEJO
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	ET	AAU	ADDIS ABABA UNIVERSITY
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	DE	EUROPEAN VACCINE INITIATIVE e.V.	EUROPEAN VACCINE INITIATIVE E.V.
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	NL	BPRC	STICHTING BIOMEDICAL PRIMATE
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	KE	Kenya Medical Research Institute	Kenya Medical Research Institute
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	IT	Takis	TAKIS SRL
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	ES	FUNDACION PARA LA INVESTIGACION	FUNDACION PARA LA INVESTIGACIÓN
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	GH	UNIVERSITY OF GHANA	UNIVERSITY OF GHANA
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	BE	ITM	INSTITUUT VOOR TROPISCHE
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	ES	ISCIH	INSTITUTO DE SALUD CARLOS III

ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant	TR	Ege University Vaccine Development	Ege University Vaccine Development
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant - AP	CO	UNIVERSIDAD DE ANTIOQUIA	UNIVERSIDAD DE ANTIOQUIA
ACCELERATING THE DEVELOPMENT OF A PROPHYLACTIC VACCINE FOR VISCERAL LEISHMANIASIS IN SUB-SAHARAN AFRICA	Below Threshold	Participant - AP	US	SEATTLE BIOMED	SEATTLE BIOMEDICAL RESEARCH
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Coordinator	NL	TBVI	STICHTING TUBERCULOSIS VACCINE
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	UK	AAHI	Access to Advanced Health (UK) LTD
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	ZA	SATVI	UNIVERSITY OF CAPE TOWN
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	ZA	Aurum	THE AURUM INSTITUTE NPC
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	NG	OAU	OBAFEMI AWOLOWO UNIVERSITY
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	ZA	Afrigen	Afrigen Biologics Pty Ltd
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa	Main list	Participant	ZA	BIC	Bioinformatico
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Coordinator	DE	BioNTech SE	BIONTECH SE
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	ZA	Centre for the AIDS Programme of Research in	Centre for the AIDS Programme of Research in
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	ZA	THE AURUM INSTITUTE NPC	THE AURUM INSTITUTE NPC
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	UG	UNHRO	UGANDA NATIONAL HEALTH
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	UG	JOINT CLINICAL RESEARCH CENTRE	JOINT CLINICAL RESEARCH CENTRE
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	MZ	INS	Instituto Nacional de Saúde
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	ZA	AFRICA HEALTH RESEARCH	AFRICA HEALTH RESEARCH
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	GA	CERMEL	Centre de Recherches Medicales de
Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant	MZ	FM	FUNDACAO MANHICA

Accelerating Development of Tuberculosis Vaccines Through Clinical Research and Methodological Innovation in Africa	Reserve list	Participant - AF	ES	ISGLOBAL	FUNDACION PRIVADA INSTITUTO DE
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Coordinator	NL	TBVI	STICHTING TUBERCULOSIS VACCINE
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Participant	ET	ARMAUER HANSEN RESEARCH	ARMAUER HANSEN RESEARCH
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Participant	CA	MCMMASTER UNIVERSITY	MCMMASTER UNIVERSITY
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Participant	NL	AIGHD Foundation	STICHTING AMSTERDAM INSTITUTE FOR
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
Safety and immunogenicity of inhaled aerosol AdHu5Ag85A vaccination against tuberculosis: A multi-center, randomized, double-blind, placebo-controlled phase II clinical trial	Below Threshold	Participant	IE	Aerogen	AEROGEN LTD
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Coordinator	ES	BIOFABRI SL	BIOFABRI SL
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	NL	TBVI	STICHTING TUBERCULOSIS VACCINE
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	NL	STICHTING	STICHTING INTERNATIONAL AIDS
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ZA	IAVI South Africa	IAVI South Africa NPC
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant - AF	US	INTERNATIONAL AIDS VACCINE	INTERNATIONAL AIDS VACCINE
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ZA	ENHANCING CARE FOUNDATION	ENHANCING CARE FOUNDATION
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ES	UNIVERSIDAD DE ZARAGOZA	UNIVERSIDAD DE ZARAGOZA
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ZA	UNIVERSITY OF CAPE TOWN LUNG	UNIVERSITY OF CAPE TOWN LUNG
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	ZA	WHC	WITS HEALTH CONSORTIUM (PTY) LTD
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
Advancing a Vaccine for Adolescent/Adult and Neonatal TB Epidemic	Main list	Participant	KE	IAVI AFRICA	IAVI AFRICA LIMITED

Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Coordinator	NL	TBVI	STICHTING TUBERCULOSIS VACCINE
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Participant	ZA	THE AURUM INSTITUTE NPC	THE AURUM INSTITUTE NPC
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Participant	DK	SSI	STATENS SERUM INSTITUT
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL
Establishing Safety, Potent Immunity & Optimal Tuberculosis Vaccine Dose of H107e/CAF10b Including in younger and older age groups in high burden Trial sites	Reserve list	Participant	GW	INASA	INSTITUTO NACIONAL DE SAUDE
EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS: T5 TRVAC	Main list	Coordinator	UK	UOXF	THE CHANCELLOR, MASTERS AND
EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS: T5 TRVAC	Main list	Participant	UG	UNHRO	UGANDA NATIONAL HEALTH
EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS: T5 TRVAC	Main list	Participant	SN	INSTITUT DE RECHERCHE EN SANTE	RESEAU AFRICAIN DE RECHERCHE
EVALUATING A MULTI-VALENT AEROSOL BOOSTER TB VACCINE FOR ADOLESCENTS AND YOUNG ADULTS IN DIVERSE AFRICAN SETTINGS: T5 TRVAC	Main list	Participant	NL	TBVI	STICHTING TUBERCULOSIS VACCINE

Legal type	Is SME?	Total costs	Requested EU contribution
Private for Profit	N	14.315.973,00 €	0,00 €
Research Organisation	N	1.409.687,50 €	1.409.687,50 €
Other	N	154.873,75 €	0,00 €
Higher or Secondary Education	N	207.295,00 €	207.295,00 €
Research Organisation	N	2.008.650,00 €	2.008.650,00 €
Research Organisation	N	1.689.435,00 €	1.689.435,00 €
Research Organisation	N	1.569.231,75 €	1.569.231,75 €
Research Organisation	N	390.253,75 €	390.253,75 €
Research Organisation	N	337.542,50 €	337.542,50 €
Higher or Secondary Education	N	805.198,50 €	805.198,50 €
Higher or Secondary Education	N	3.638.758,75 €	3.164.015,59 €
Other	N	556.908,75 €	556.908,75 €
Higher or Secondary Education	N	3.383.498,75 €	2.773.667,19 €
Higher or Secondary Education	N	628.543,75 €	410.918,75 €
Higher or Secondary Education	N	647.562,50 €	409.312,50 €
Higher or Secondary Education	N	484.800,00 €	453.550,00 €
Research Organisation	N	989.656,25 €	369.730,21 €

Research Organisation	N	476.532,50 €	476.532,50 €
Research Organisation	N	523.437,50 €	492.187,50 €
Research Organisation	N	202.855,00 €	172.855,00 €
Private for Profit	Y	520.312,50 €	520.312,50 €
Public Body	N	1.890.715,00 €	0,00 €
Public Body	N	150.000,00 €	0,00 €
Public Body	N	113.000,00 €	0,00 €
Public Body	N	231.375,00 €	0,00 €
Public Body	N	200.000,00 €	0,00 €
Research Organisation	N	2.495.250,00 €	2.495.250,00 €
Research Organisation	N	3.000.250,00 €	3.000.250,00 €
Higher or Secondary Education	N	577.690,00 €	577.690,00 €
Other	N	918.750,00 €	918.750,00 €
Higher or Secondary Education	N	1.299.875,00 €	1.299.875,00 €
Higher or Secondary Education	N	371.905,00 €	371.905,00 €
Higher or Secondary Education	N	410.000,00 €	410.000,00 €
Higher or Secondary Education	N	563.496,25 €	563.496,25 €
Private for Profit	Y	502.000,00 €	502.000,00 €
Private for Profit	N	0,00 €	0,00 €
Higher or Secondary Education	N	900.000,00 €	900.000,00 €

Higher or Secondary Education	N	1.147.187,50 €	1.147.187,50 €
Research Organisation	N	1.766.312,50 €	1.766.312,50 €
Research Organisation	N	2.665.000,00 €	2.665.000,00 €
Higher or Secondary Education	N	2.600.012,50 €	2.600.012,50 €
Higher or Secondary Education	N	395.783,75 €	395.783,75 €
Higher or Secondary Education	N	501.525,00 €	501.525,00 €
Higher or Secondary Education	N	368.750,00 €	368.750,00 €
Other	N	1.435.000,00 €	560.000,00 €
Private for Profit	N	24.750.000,00 €	0,00 €
Higher or Secondary Education	N	924.500,25 €	924.500,25 €
Private for Profit	N	706.826,25 €	706.826,25 €
Research Organisation	N	1.259.770,00 €	1.259.770,00 €
Research Organisation	N	570.072,50 €	570.072,50 €
Higher or Secondary Education	N	719.650,00 €	719.650,00 €
Research Organisation	N	1.540.223,75 €	1.540.223,75 €
Higher or Secondary Education	N	589.262,50 €	589.262,50 €
Research Organisation	N	1.744.693,75 €	1.744.693,75 €
Public Body	N	1.685.001,00 €	1.685.001,00 €
Research Organisation	N	2.468.001,25 €	2.468.001,25 €
Higher or Secondary Education	N	2.043.008,75 €	2.043.008,75 €

Research Organisation	N	1.737.565,00 €	1.737.565,00 €
Research Organisation	N	1.546.582,50 €	1.546.582,50 €
Other	N	1.638.486,25 €	1.638.486,25 €
Research Organisation	N	1.496.637,50 €	1.496.637,50 €
Research Organisation	N	1.641.877,50 €	1.641.877,50 €
Higher or Secondary Education	N	0,00 €	0,00 €
Higher or Secondary Education	N	0,00 €	0,00 €
Higher or Secondary Education	N	2.256.538,75 €	1.671.726,25 €
Higher or Secondary Education	N	1.231.132,50 €	1.231.132,50 €
Research Organisation	N	271.171,25 €	271.171,25 €
Research Organisation	N	1.346.428,75 €	1.346.428,75 €
Private for Profit	N	250.000,00 €	0,00 €
Research Organisation	N	383.806,25 €	383.806,25 €
Higher or Secondary Education	N	808.001,25 €	404.001,25 €
Higher or Secondary Education	N	438.528,75 €	277.703,75 €
Research Organisation	N	175.162,50 €	175.162,50 €
Research Organisation	N	110.425,00 €	110.425,00 €
Research Organisation	N	2.031.946,25 €	1.323.696,25 €
Research Organisation	N	1.461.837,50 €	1.461.837,50 €
Public Body	N	1.700.000,00 €	0,00 €

Public Body	N	1.700.000,00 €	0,00 €
Higher or Secondary Education	N	2.429.672,50 €	429.672,50 €
Higher or Secondary Education	N	1.399.174,50 €	399.174,50 €
Private for Profit	N	5.039.106,25 €	4.139.106,30 €
Research Organisation	N	5.330.020,00 €	1.358.037,00 €
Higher or Secondary Education	N	642.761,25 €	642.761,25 €
Higher or Secondary Education	N	0,00 €	0,00 €
Research Organisation	N	1.172.422,50 €	1.172.422,50 €
Higher or Secondary Education	N	2.939.996,25 €	2.939.996,25 €
Private for Profit	N	15.887.500,00 €	37.500,00 €
Other	N	1.853.750,00 €	18.750,00 €
Higher or Secondary Education	N	402.500,00 €	402.500,00 €
Research Organisation	N	1.240.062,50 €	1.240.062,50 €
Other	N	1.371.250,00 €	1.371.250,00 €
Research Organisation	N	1.240.307,50 €	1.240.307,50 €
Higher or Secondary Education	N	1.200.942,50 €	1.200.942,50 €
Higher or Secondary Education	N	386.896,25 €	386.896,25 €
Higher or Secondary Education	N	285.550,00 €	285.550,00 €
Higher or Secondary Education	N	3.465.000,00 €	3.465.000,00 €
Research Organisation	N	579.133,75 €	579.133,75 €

Research Organisation	N	1.170.085,25 €	1.170.085,25 €
Research Organisation	N	1.312.500,00 €	1.312.500,00 €
Public Body	N	1.126.913,75 €	1.126.913,75 €
Other	N	1.000.000,00 €	1.000.000,00 €
Research Organisation	N	1.574.493,75 €	1.574.493,75 €
Research Organisation	N	5.071.805,25 €	5.071.805,25 €
Research Organisation	N	833.661,25 €	833.661,25 €
Research Organisation	N	7.360.932,50 €	7.360.932,50 €
Private for Profit	N	262.176,25 €	262.176,25 €
Higher or Secondary Education	N	642.598,75 €	642.598,75 €
Higher or Secondary Education	N	867.942,50 €	867.942,50 €
Higher or Secondary Education	N	3.088.637,50 €	3.088.637,50 €
Other	N	677.500,00 €	677.500,00 €
Private for Profit	N	1.565.587,50 €	1.565.587,50 €
Higher or Secondary Education	N	8.922.590,50 €	8.922.590,50 €
Other	N	388.187,50 €	388.187,50 €
Research Organisation	N	2.517.587,50 €	2.517.587,50 €
Research Organisation	N	1.844.995,00 €	1.844.995,00 €
Higher or Secondary Education	N	1.081.166,25 €	1.081.166,25 €
Research Organisation	N	998.642,50 €	998.642,50 €

Research Organisation	N	713.500,00 €	713.500,00 €
Private for Profit	N	0,00 €	0,00 €
Higher or Secondary Education	N	1.071.287,50 €	1.071.287,50 €
Public Body	N	0,00 €	0,00 €
Research Organisation	N	2.067.590,00 €	2.067.590,00 €
Research Organisation	N	1.718.725,00 €	1.718.725,00 €
Higher or Secondary Education	N	1.250.000,00 €	1.250.000,00 €
Higher or Secondary Education	N	795.000,00 €	795.000,00 €
Research Organisation	N	2.225.036,25 €	2.225.036,25 €
Research Organisation	N	1.250.000,00 €	1.250.000,00 €
Higher or Secondary Education	N	3.430.671,25 €	3.430.671,25 €
Research Organisation	N	3.558.918,75 €	3.558.918,75 €
Research Organisation	N	3.498.316,25 €	3.498.316,25 €
Private for Profit	N	233.250,00 €	233.250,00 €
Higher or Secondary Education	N	981.017,50 €	981.017,50 €
Research Organisation	N	884.902,50 €	884.902,50 €
Higher or Secondary Education	N	706.980,00 €	706.980,00 €
Private for Profit	Y	401.878,75 €	401.878,75 €
Research Organisation	N	2.096.250,00 €	2.096.250,00 €
Higher or Secondary Education	N	2.935.677,50 €	2.935.677,50 €

Research Organisation	Y	3.206.872,50 €	3.206.872,50 €
Research Organisation	N	563.000,00 €	563.000,00 €
Research Organisation	N	2.640.148,75 €	2.640.148,75 €
Other	N	860.731,25 €	860.731,25 €
Private for Profit	N	1.808.031,75 €	1.808.031,75 €
Higher or Secondary Education	N	5.185.449,50 €	5.185.449,50 €
Research Organisation	N	4.578.002,50 €	4.578.002,50 €
Other	N	1.346.403,75 €	1.346.403,75 €
Research Organisation	N	2.628.523,75 €	2.628.523,75 €
Private for Profit	N	31.250,00 €	31.250,00 €
Higher or Secondary Education	N	1.243.837,50 €	1.243.837,50 €
Higher or Secondary Education	N	269.612,50 €	269.612,50 €
Higher or Secondary Education	N	3.563.231,25 €	3.563.231,25 €
Higher or Secondary Education	N	415.052,50 €	415.052,50 €
Higher or Secondary Education	N	1.573.260,25 €	1.573.260,25 €
Higher or Secondary Education	N	1.167.450,00 €	1.167.450,00 €
Research Organisation	N	4.621.625,00 €	4.621.625,00 €
Higher or Secondary Education	N	482.541,25 €	482.540,00 €
Higher or Secondary Education	N	836.551,25 €	836.551,25 €
Higher or Secondary Education	N	1.872.771,25 €	1.872.771,25 €

Private for Profit	N	0,00 €	0,00 €
Higher or Secondary Education	N	822.450,00 €	822.450,00 €
Higher or Secondary Education	N	4.520.985,00 €	4.520.985,00 €
Higher or Secondary Education	N	1.194.423,75 €	1.194.423,75 €
Research Organisation	N	4.500.000,00 €	4.500.000,00 €
Higher or Secondary Education	N	1.095.695,00 €	1.095.695,00 €
Private for Profit	N	610.000,00 €	500.000,00 €
Other	N	1.779.288,75 €	1.779.288,75 €
Higher or Secondary Education	N	6.976.669,25 €	6.976.669,25 €
Private for Profit	Y	738.625,00 €	738.625,00 €
Higher or Secondary Education	N	1.495.986,25 €	1.495.986,25 €
Higher or Secondary Education	N	1.471.250,00 €	1.471.250,00 €
Higher or Secondary Education	N	741.757,50 €	741.757,50 €
Higher or Secondary Education	N	559.063,75 €	559.063,75 €
Higher or Secondary Education	N	487.431,25 €	487.431,25 €
Higher or Secondary Education	N	542.785,00 €	542.785,00 €
Other	N	538.997,50 €	538.997,50 €
Other	N	1.122.152,50 €	1.122.152,50 €
Public Body	N	0,00 €	0,00 €
Research Organisation	N	0,00 €	0,00 €

Higher or Secondary Education	N	0,00 €	0,00 €
Higher or Secondary Education	N	1.563.625,00 €	1.563.625,00 €
Research Organisation	N	1.922.700,00 €	1.922.700,00 €
Research Organisation	N	1.669.835,00 €	1.669.835,00 €
Higher or Secondary Education	N	1.704.690,00 €	1.704.690,00 €
Higher or Secondary Education	N	1.670.315,00 €	1.670.315,00 €
Higher or Secondary Education	N	510.980,00 €	510.980,00 €
Higher or Secondary Education	N	850.000,00 €	850.000,00 €
Higher or Secondary Education	N	2.986.365,00 €	2.986.365,00 €
Research Organisation	N	2.121.250,00 €	2.121.250,00 €
Research Organisation	N	2.489.207,50 €	2.489.207,50 €
Higher or Secondary Education	N	1.355.631,25 €	1.355.631,25 €
Research Organisation	N	1.937.500,00 €	1.937.500,00 €
Research Organisation	N	759.163,75 €	759.163,75 €
Public Body	N	1.918.995,00 €	1.918.995,00 €
Private for Profit	Y	2.298.921,25 €	2.298.921,25 €
Other	N	1.497.812,50 €	1.497.812,50 €
Higher or Secondary Education	N	830.113,75 €	830.113,75 €
Higher or Secondary Education	N	723.802,50 €	723.802,50 €
Research Organisation	N	664.250,00 €	664.250,00 €

Higher or Secondary Education	N	448.597,50 €	448.597,50 €
Higher or Secondary Education	N	0,00 €	0,00 €
Research Organisation	N	0,00 €	0,00 €
Other	N	850.000,00 €	825.000,00 €
Research Organisation	Y	5.140.418,75 €	3.199.427,00 €
Higher or Secondary Education	N	2.601.207,50 €	2.601.207,00 €
Research Organisation	N	2.677.073,75 €	2.490.646,00 €
Higher or Secondary Education	N	291.798,75 €	291.798,75 €
Other	N	1.110.232,50 €	844.305,00 €
Private for Profit	N	1.691.085,75 €	1.691.085,00 €
Private for Profit	Y	22.268.986,25 €	22.268.986,25 €
Higher or Secondary Education	N	1.871.842,50 €	1.871.842,50 €
Research Organisation	N	2.291.632,50 €	2.291.632,50 €
Research Organisation	N	1.652.568,75 €	1.652.568,75 €
Research Organisation	N	1.890.559,00 €	1.890.559,00 €
Higher or Secondary Education	N	1.883.986,25 €	1.883.986,25 €
Research Organisation	N	1.656.712,50 €	1.656.712,50 €
Other	N	1.921.741,25 €	1.921.741,25 €
Research Organisation	N	1.559.031,25 €	1.559.031,25 €
Research Organisation	N	1.768.346,25 €	1.768.346,25 €

Research Organisation	N	468.708,75 €	468.708,75 €
Other	N	625.000,00 €	600.000,00 €
Research Organisation	N	2.601.610,00 €	1.525.950,00 €
Higher or Secondary Education	N	8.108.500,00 €	4.920.000,00 €
Research Organisation	N	888.127,50 €	888.127,50 €
Research Organisation	N	2.406.800,00 €	1.500.051,00 €
Private for Profit	Y	255.000,00 €	30.000,00 €
Private for Profit	N	10.128.845,50 €	3.295.230,19 €
Other	N	1.245.000,00 €	1.245.000,00 €
Other	N	1.962.305,00 €	1.537.353,69 €
Research Organisation	N	8.587.618,50 €	6.078.698,26 €
Research Organisation	N	37.345.957,25 €	0,00 €
Research Organisation	N	2.092.196,25 €	0,00 €
Research Organisation	N	1.120.000,00 €	1.120.000,00 €
Higher or Secondary Education	N	7.572.316,25 €	1.803.444,25 €
Higher or Secondary Education	N	106.250,00 €	0,00 €
Research Organisation	N	1.164.262,50 €	1.164.262,29 €
Private for Profit	N	1.465.117,50 €	0,00 €
Research Organisation	N	1.120.001,25 €	1.120.000,78 €
Research Organisation	N	1.674.468,75 €	859.029,31 €

Other	N	806.250,00 €	781.250,00 €
Research Organisation	N	5.882.832,50 €	2.600.518,00 €
Research Organisation	N	15.593.274,75 €	6.088.537,00 €
Higher or Secondary Education	N	2.747.337,50 €	2.747.337,00 €
Research Organisation	N	1.366.223,75 €	1.366.223,00 €
Research Organisation	N	1.870.136,25 €	1.554.935,00 €
Higher or Secondary Education	N	7.414.661,75 €	7.414.661,75 €
Research Organisation	N	3.305.091,75 €	3.305.091,75 €
Other	N	1.298.574,00 €	1.298.574,00 €
Other	N	668.750,00 €	668.750,00 €

ANNEX 7 Table 8: Country participation and share of requested EU contribution in evaluated and retained for funding proposals

Country Group	Country	N. Participations in evaluated proposals	N. Participations in retained for funding proposals	%	Requested EU contribution in evaluated proposals	Requested EU contribution in retained for funding proposals	%
Associated Countries	Türkiye	1	0	0,00 %	448.597,50 €	0,00 €	0,00 %
Associated Countries	United Kingdom	22	4	18,18 %	54.402.648,94 €	11.338.527,50 €	20,84 %
Associated Countries		23	4	17,39 %	54.851.246,44 €	11.338.527,50 €	20,67 %
EU Member States	Austria	5	2	40,00 %	8.432.360,59 €	3.663.921,25 €	43,45 %
EU Member States	Belgium	6	0	0,00 %	6.699.676,25 €	0,00 €	0,00 %
EU Member States	Czechia	1	0	0,00 %	542.785,00 €	0,00 €	0,00 %
EU Member States	Denmark	1	0	0,00 %	6.088.537,00 €	0,00 €	0,00 %
EU Member States	France	13	9	69,23 %	8.216.986,25 €	4.638.712,50 €	56,45 %
EU Member States	Germany	19	5	26,32 %	37.326.050,00 €	1.969.550,00 €	5,28 %
EU Member States	Ireland	2	0	0,00 %	568.997,50 €	0,00 €	0,00 %
EU Member States	Italy	3	1	33,33 %	3.400.608,75 €	713.500,00 €	20,98 %
EU Member States	Netherlands	10	5	50,00 %	9.119.828,69 €	5.448.526,19 €	59,74 %
EU Member States	Spain	11	5	45,45 %	12.819.381,44 €	5.589.820,19 €	43,60 %
EU Member States	Sweden	3	1	33,33 %	1.586.710,00 €	706.980,00 €	44,56 %
EU Member States		74	28	37,84 %	94.801.921,47 €	22.731.010,13 €	23,98 %
Third countries	Brazil	1	1	100,00 %	1.312.500,00 €	1.312.500,00 €	100,00 %

Third countries	Burkina Faso	7	1	14,29 %	13.463.421,30 €	1.371.250,00 €	10,19 %
Third countries	Burundi	1	0	0,00 %	2.600.012,50 €	0,00 €	0,00 %
Third countries	Cameroon	1	0	0,00 %	1.471.250,00 €	0,00 €	0,00 %
Third countries	Canada	1	0	0,00 %	4.920.000,00 €	0,00 €	0,00 %
Third countries	Colombia	1	0	0,00 %	0,00 €	0,00 €	0,00 %
Third countries	Congo	1	0	0,00 %	918.750,00 €	0,00 €	0,00 %
Third countries	Congo (Democratic Republic of)	4	1	25,00 %	5.277.971,25 €	1.250.000,00 €	23,68 %
Third countries	Cote d'Ivoire	1	0	0,00 %	1.685.001,00 €	0,00 €	0,00 %
Third countries	Egypt	1	1	100,00 %	0,00 €	0,00 €	0,00 %
Third countries	Ethiopia	11	1	9,09 %	14.345.115,00 €	402.500,00 €	2,81 %
Third countries	Gabon	7	4	57,14 %	11.372.135,00 €	6.639.998,75 €	58,39 %
Third countries	Gambia	3	0	0,00 %	4.869.730,21 €	0,00 €	0,00 %
Third countries	Ghana	10	3	30,00 %	12.111.635,00 €	2.921.726,25 €	24,12 %
Third countries	Guinea-Bissau	3	0	0,00 %	2.031.467,50 €	0,00 €	0,00 %
Third countries	India	1	1	100,00 %	0,00 €	0,00 €	0,00 %
Third countries	Kenya	10	5	50,00 %	15.017.488,59 €	8.352.750,09 €	55,62 %
Third countries	Korea (Republic of)	3	2	66,67 %	9.418.091,50 €	7.296.841,50 €	77,48 %
Third countries	Madagascar	1	0	0,00 %	1.704.690,00 €	0,00 €	0,00 %
Third countries	Malawi	3	0	0,00 %	1.949.536,25 €	0,00 €	0,00 %
Third countries	Mali	6	4	66,67 %	6.112.728,75 €	4.442.300,00 €	72,67 %

Third countries	Mozambique	6	2	33,33 %	8.953.375,00 €	2.108.978,75 €	23,56 %
Third countries	Nigeria	3	3	100,00 %	2.418.712,50 €	2.418.712,50 €	100,00 %
Third countries	Rwanda	2	1	50,00 %	3.727.176,25 €	3.465.000,00 €	92,97 %
Third countries	Senegal	3	2	66,67 %	9.829.591,75 €	2.468.659,25 €	25,11 %
Third countries	South Africa	20	10	50,00 %	35.933.223,05 €	17.478.846,30 €	48,64 %
Third countries	Switzerland	7	4	57,14 %	4.065.268,75 €	1.037.267,50 €	25,52 %
Third countries	Tanzania (United Republic of)	10	3	30,00 %	20.407.122,25 €	6.187.548,00 €	30,32 %
Third countries	Uganda	11	4	36,36 %	17.040.150,25 €	7.657.306,75 €	44,94 %
Third countries	United States	11	3	27,27 %	5.653.347,50 €	1.071.287,50 €	18,95 %
Third countries		150	56	37,33 %	218.609.491,15 €	77.883.473,14 €	35,63 %
GRAND TOTAL		247	88	35,63 %	368.262.659,06 €	111.953.010,77 €	30,40 %